Warning: file_get_contents(https://multipass.sense-studios.com/check_token/-1?url=%2Fcontent%2Ffeatured%2Fletter-from-the-editor-20%2F&agent=CCBot%2F2.0+%28https%3A%2F%2Fcommoncrawl.org%2Ffaq%2F%29&name=dev.mc.sense-studios.com&ip=3.93.74.25&categories=Featured%7CAAN+2017): failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 114

Notice: Trying to get property 'status' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 117

Notice: Trying to get property 'access_type' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 123
Letter from the Editor - Medical Conferences

Home > Letter from the Editor

Letter from the Editor

Editor
Prof. Nikolaos Grigoriadis, Aristotle University of Thessaloniki, Greece

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
AAN 2017
Dear Reader,

A whole spectrum of neurological disorder studies was represented in the AAN, 21-27 April 2017, Boston. This newsletter compiles a number of studies related to risk-factor identification, clinical trials, pivotal clinical trial extension, real world data, innovative therapeutic approaches, presented in this meeting. The effect of intensive reduction of systolic blood pressure (BP) on hematoma expansion after intra-cerebral haemorrhage (ICH), were discussed. The identification of BP as the most important risk factor contributing to stroke and dementia, the potential ineffectiveness of cholinesterase inhibitors in mild cognitive impairment, the new guidelines on Sudden Unexpected Death in Epilepsy, the cannabidiol use for epilepsy, were presented. Immune therapies in migraine, the use of extended-release carbidopa-levodopa, subcutaneous apomorphine, and gene therapy in PD, were also presented. MS – related studies were impressively many. Among them, the use of autologous EBV-specific T-cells in PPMS, the con-current use of opicinumab and (IFN) beta-1a, im, in active RRMS or SPMS, the robust effects siponimod in SPMS, the use of dimethyl fumarate (DMF) in paediatric MS, data from the extension studies of Alemtuzumab, the rapid effect of ocrelizumab and the efficacy of cladribine tablets, were among the most spectacular news at the meeting.

Best Regards,

Professor Nikolaos Grigoriadis



Posted on